Search Results for: lung cancer

The coverage decision means that more than 49 million eligible Medicare enrollees in the United States will now be able to benefit from VeriStrat being a covered diagnostic test, according to specific lung cancer indications outlined by Novitas.

Robust discussion follows disclosure of an attempt to foil cancer.

This is the first FDA-approved companion diagnostic that detects epidermal growth factor receptor gene mutations, which are present in approximately 10% of non-small cell lung cancers.